Chemclin Diagnostics Co., Ltd.
688468.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.68B
Close$
$1.29
80.4% downside
Current Fair Value
80.4% downsideOvervalued by 80.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.68 Billion |
|---|---|
| Enterprise Value | $2.75 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.11 |
| Beta | 0.07 |
| Outstanding Shares | 328,763,350 |
Return
| Return on Equity | 2.50% |
|---|---|
| Return on Assets | 2.01% |
| Return on Invested Capital | 2.65% |
Valuation & Multiples
| P/E Ratio | 79.45 |
|---|---|
| PEG | -241.56 |
| Price to Sales | - |
| Price to Book Ratio | 1.65 |
| Enterprise Value to Revenue | 8.52 |
| Enterprise Value to EBIT | 64.37 |
| Enterprise Value to Net Income | 77 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Chemclin Diagnostics Co., Ltd.
573 employees
CEO: Lin Li Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on phot...